Who is sponsoring NCT00698555?

NCT00698555 is sponsored by GlaxoSmithKline.

What condition does NCT00698555 study?

NCT00698555 studies Hepatitis B.

What drugs are being tested in NCT00698555?

Interventions: HBV-MPL vaccine, Engerix™-B.

What is the status of NCT00698555?

NCT00698555 is currently COMPLETED.

Last reviewed 2008-06-16 · How we verify

Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 18-40 Years

NCT00698555 Phase 2 COMPLETED

This study will evaluate the immunogenicity and safety of different formulations of the candidate HBV-MPL vaccine administered according to a 2-dose schedule and compare it to that of Engerix™-B administered according to a 3-dose schedule in order to determine the optimal dose of each component of the candidate HBV-MPL vaccine when administered at 0 and 6 months

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	COMPLETED
Enrolment	163
Start date	1997-03

Conditions

Hepatitis B

Interventions

HBV-MPL vaccine
Engerix™-B

Primary outcomes

Anti-HBs antibody concentrations — Month 7

Countries

Belgium